SlideShare a Scribd company logo
DOSING IN CHILDRENS
Dr. Ramesh Bhandari
Asst. Professor
Department of Pharmacy Practice
KLE College of Pharmacy, Belagavi
Dr.
Ramesh
Bhandari
Asst.
Profesor
• Infants and children have different dosing
requirements than adults.
• Paediatric patients were considered mini
adults in the past.
• Paediatric patient shows physiological
variability and so it is important to select
an appropriate dose for a paediatric patient.
Dr.
Ramesh
Bhandari
Asst.
Profesor
• The development of organs continue until
the age of 12 years.
• The variation in body composition and
the maturity of liver, kidney, and other
organ functions are potential sources of
differences in pharmacokinetics with
respect to age.
Dr.
Ramesh
Bhandari
Asst.
Profesor Classification of paediatric patients
1. Preterm Neonate (<37 weeks of gestation)
2. Neonate (Birth to 28 days)
3. Infant & Toddlers (28 days to 23 months)
4. Young child (2 to 5 years)
5. Older child (6 to 11 Years)
6. Adolescent (12 to 18 Years)
Dr.
Ramesh
Bhandari
Asst.
Profesor
• When dosage guidelines are not available
for a drug, empirical dose adjustment
methods are often used.
• These empirical dose adjustment methods
are based on body surface area or body
weight.
• However, pharmacokinetic parameters may
vary as a function of age.
Dr.
Ramesh
Bhandari
Asst.
Profesor • Dosage based on body surface area has the
advantage of avoiding some bias due to
obesity or unusual body weight, because the
height and the weight of the patient are both
considered.
• The body surface area method gives only a
rough estimation of the proper dose, because
the pharmacokinetic differences between
patients of the same body surface area are not
considered.
Dr.
Ramesh
Bhandari
Asst.
Profesor
• Dosage regimens for the newborn, infant,
and child must consider the changing
physiologic development of the patient
and the pharmacokinetics of the specific
drug for that age group.
Dr.
Ramesh
Bhandari
Asst.
Profesor ABSORPTION
 Gastric pH is 6-8 at birth, but drops to pH 1–3
within 24 hours of birth
 Gastric acid secretion then declines (Achlorhydria)
during 8–30 days, and does not approach adult
values until approximately 3 years of age
 This lower level of gastric acid secretion contributes
to the increased bioavailability of acid-labile drugs
in neonates compared to older children and adults
(E.g.: Penicillin G, Ampicillin)
Dr.
Ramesh
Bhandari
Asst.
Profesor
 Gastric emptying is delayed (upto 6 – 8 hours) and
irregular in the neonate and infant, but approaches adult
values by 6–8 months of age.
 Intestinal motility (peristalsis) is also irregular,
unpredictable and only partially dependent on feeding
patterns in newborn until 1 year.
 In newborns, decreased GI motility can delay drug
absorption and result in lower peak plasma drug
concentrations, but does not alter the fraction of drug
absorbed for most drugs.
 In older infants and children, GI transit time may be
increased.
Dr.
Ramesh
Bhandari
Asst.
Profesor
Physiologic
Variable
Age Group PK Result Example
↑ gastric pH Neonates, Infants,
Young Children
↑ BA of basic drugs and acid
labile drugs
↓ BA of acidic drugs
Ampicillin,
Penicillin G
Phenobarbital
(acidic)
↓ gastric and
intestinal motility
Neonates, Infants Unpredictable BA Digoxin
↑gastric and
intestinal motility
Older Infants,
Children
Unpredictable BA Digoxin
↓bile acid
production
Neonates ↓ BA Vitamin E,
Vitamin K
Bacterial Flora Neonates and Infants ↑ BA Digoxin
Dr.
Ramesh
Bhandari
Asst.
Profesor Drug Absorption in Paediatric patients
Physiologic
Variables
Neonate Infants Children
Gastric emptying time
Gastric pH
Intestinal motility
Intestinal surface area
Muscular blood flow
Irregular
>5
Reduced
Reduced
Reduced
Increased
2 to 4
Increased
Near adult
Increased
Slightly increased
Normal (2-3)
Slightly increased
Adult pattern
Adult pattern
Dr.
Ramesh
Bhandari
Asst.
Profesor Paediatric Changes in route of administration
Parameter Neonate Infants Children
Oral absorption
IM absorption
Percutaneous
absorption
Rectal absorption
Erratic or
reduced
variable
Increased
Very efficient
↑ rate
Increased
Increased
Efficient
Near adult pattern
Adult pattern
Near Adult pattern
Near adult pattern
Dr.
Ramesh
Bhandari
Asst.
Profesor Examples
Gastrointestinal Drug Absorption
Increased in
Newborns
Infants = adults Decreased in
newborns
Penicillin Theophylline Phenytoin
Ampicillin Sulfonamides Acetaminophen
Erythromycin Phenobarbitol
Digoxin
Zidovudine
Dr.
Ramesh
Bhandari
Asst.
Profesor DISTRIBUTION
• Some of the factors that determine drug
distribution within the body are subject to
change with age.
• These includes vascular perfusion, body
composition, tissue binding characteristics
and the extent of plasma protein binding.
Dr.
Ramesh
Bhandari
Asst.
Profesor
Extracellular fluid volume and total body water as a percentage of
body weight at different life stages
Age Total body water (%) Extracellular fluid (%)
Preterm Neonates 85 50
Term Neonate 75 45
3 Months 75 30
1 year 60 25
Adult 60 20
Dr.
Ramesh
Bhandari
Asst.
Profesor Plasma protein binding and drug distribution
Parameters Neonate Infants Children
Plasma Albumin and
total Globulin
Decreased Approx. Normal Approx adult
Total protein Decreased Decreased Approx adult
Adipose Tissue Less Decreased Reduced
Total Body water Increased Increased Approx adult
Extracellular water Increased Increased Approx adult
Hydrophilic drugs Vd Increased Increased Slightly increased
Hydrophobic drugs Vd Decreased Decreased Slightly decreased
Dr.
Ramesh
Bhandari
Asst.
Profesor
METABOLISM
• At birth, majority of the metabolic enzyme systems are
either absent or present in considerably reduced amounts
(20 % - 70 %) compared to adults (Exemptions: Sulphate
conjugation is more).
• This reduced capacity for metabolic degradation at birth
is followed by dramatic increase in the metabolic rate in
the older infant and young child.
• In the age group 1-9 years in particular metabolic
clearance of drugs is shown to be greater than in adults as
shown by Theophylline, phenytoin and carbamazepine.
Dr.
Ramesh
Bhandari
Asst.
Profesor
Example
Theophylline dosage in children older than 1 year
Age Dosage (mg/kg/day)
1-9 years 24
9-12 years 20
12-16 years 18
Adult 13
Dr.
Ramesh
Bhandari
Asst.
Profesor • Glucuronidation is very less. Therefore
chloramphenicol is not bound extensively
and so poor elimination results in
accumulation of chloramphenicol that
leads to Gray baby syndrome.
• Drugs that are extensively metabolized by
liver should be administered cautiously
like caffeine, lidocaine, chloramphenicol.
Dr.
Ramesh
Bhandari
Asst.
Profesor Parameter Neonate Infants Children
Liver/body weight ratio
Cytochrome P450 activity
Hepatic blood flow
Phase II enzyme activity
Metabolic rates
Increased
Reduced
Reduced
Reduced
Reduced
Increased
Increased
Increased
Increased
Increased
Slightly increased
Slightly increased
Approx. Normal
Approx. Normal
Approx. Normal
Dr.
Ramesh
Bhandari
Asst.
Profesor EXCRETION
• The anatomical and functional immaturity of
the kidneys at birth limits the renal excretory
capacity.
• Younger than 3-6 months, the GFR rate is
lower than that of adults.
• Generally the complete maturation of
glomerular and tubular function is reached
after only towards 12-18 months of age.
Dr.
Ramesh
Bhandari
Asst.
Profesor Renal Clearance of Gentamicin
Plasma Half life
(in hours)
Small premature infants weighing less than 1.5
kg
11.5
Small premature infants weighing 1.5-2 kg 8
Term infants and large premature infants less
than1 week of age
5.5
Infants 1 week to months 3-3.5
Infants more than months to adulthood 2-3
Dr.
Ramesh
Bhandari
Asst.
Profesor Therapeutic Problem in childrens
Sampling blood is difficult.
Alternative source to be considered like
urine or saliva.
While selecting dosage form oral dosage
forms are more preferred than intravenous.
Dr.
Ramesh
Bhandari
Asst.
Profesor
Factors to be considered while
selecting dosage regimen for children
i. Age
ii. Weight or Body surface area
iii. Dosage form or formulation
iv. Route of administration
v. Pharmacokinetics
vi. Interactions
Dr.
Ramesh
Bhandari
Asst.
Profesor
Some useful formulas for
Calculating child dose
Fried’s rule for infants
Age in months X Adult Dose = Dose for Infant
150
Dr.
Ramesh
Bhandari
Asst.
Profesor
Young’s rule
Age (in Years) X Adult Dose = Child dose
Age (in years) + 12
Dr.
Ramesh
Bhandari
Asst.
Profesor
Child dose based on BSA
BSA of child (m2) X Adult Dose = Child dose
1.73 M2
Haycock formula for BSA:
BSA = 0.024265 X W0.5378 X H0.3964
Dr.
Ramesh
Bhandari
Asst.
Profesor
Clark’s Rule
Weight (in lb) X Adult Dose = Child dose
150 lb
Dr.
Ramesh
Bhandari
Asst.
Profesor Practice Problem
The elimination half-life of penicillin G is
0.5 hour in adults and 3.2 hours in
neonates (0–7 days old). Assuming that the
normal adult dose of penicillin G is
4 mg/kg every 4 hours, calculate the dose
of penicillin G for an 11-lb infant.
Dr.
Ramesh
Bhandari
Asst.
Profesor

More Related Content

What's hot

NOMOGRAMS AND TABULATIONS IN DESIGNING DOSAGE REGIMEN.pptx
NOMOGRAMS AND TABULATIONS IN   DESIGNING DOSAGE REGIMEN.pptxNOMOGRAMS AND TABULATIONS IN   DESIGNING DOSAGE REGIMEN.pptx
NOMOGRAMS AND TABULATIONS IN DESIGNING DOSAGE REGIMEN.pptx
Firdous Ansari
 
Individualization of drug dosage regimen
Individualization of drug dosage regimenIndividualization of drug dosage regimen
Individualization of drug dosage regimen
Dr. Ramesh Bhandari
 
Population pharamacokinetics
Population pharamacokineticsPopulation pharamacokinetics
Population pharamacokinetics
Dr. Ramesh Bhandari
 
Therapeutic drug monitoring of seizure disorder drugs
Therapeutic drug monitoring of seizure disorder drugsTherapeutic drug monitoring of seizure disorder drugs
Therapeutic drug monitoring of seizure disorder drugs
Dr. Ramesh Bhandari
 
Individualization of dosage regimen
Individualization of dosage regimenIndividualization of dosage regimen
Individualization of dosage regimen
PARUL UNIVERSITY
 
Tdm of cardiovascual drugs
Tdm of cardiovascual drugsTdm of cardiovascual drugs
Tdm of cardiovascual drugsSenthilraj93
 
Protocol for tdm
Protocol for tdmProtocol for tdm
Protocol for tdm
SwarnaPriyaBasker
 
Adaptive method OR dosing with feedback
Adaptive method OR dosing with feedbackAdaptive method OR dosing with feedback
Adaptive method OR dosing with feedback
pavithra vinayak
 
Dosing in childrens
Dosing in childrensDosing in childrens
Dosing in childrens
Dr. Ramesh Bhandari
 
Dosing in elderly
Dosing in elderly Dosing in elderly
Dosing in elderly
Dr. Ramesh Bhandari
 
Analysis of pk data- Pop PK analysis
Analysis of pk data- Pop PK analysisAnalysis of pk data- Pop PK analysis
Analysis of pk data- Pop PK analysisGayathri Ravi
 
TDM of drugs used in organ transplantation
TDM of drugs used in organ transplantationTDM of drugs used in organ transplantation
TDM of drugs used in organ transplantation
Dr. Ramesh Bhandari
 
Therapeutic drug monitoring of organ transplantation drugs
Therapeutic drug monitoring of organ transplantation drugsTherapeutic drug monitoring of organ transplantation drugs
Therapeutic drug monitoring of organ transplantation drugs
Dr. Ramesh Bhandari
 
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disordersTherapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
Abel C. Mathew
 
Pharmacokinetic and pharmacodynamic correlation
Pharmacokinetic and pharmacodynamic correlationPharmacokinetic and pharmacodynamic correlation
Pharmacokinetic and pharmacodynamic correlation
Dr. Ramesh Bhandari
 
TDM of psychiatric drugs
TDM of psychiatric drugsTDM of psychiatric drugs
TDM of psychiatric drugs
Dr. Ramesh Bhandari
 
Designing of dosage regimen
Designing of dosage regimenDesigning of dosage regimen
Designing of dosage regimen
Dr. Ramesh Bhandari
 
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
Studies of vaccine safety (Pharmacoepidemiology)  V PharmDStudies of vaccine safety (Pharmacoepidemiology)  V PharmD
Studies of vaccine safety (Pharmacoepidemiology) V PharmDDr.Sohel Memon
 
Drug induced birth defect
Drug induced birth defectDrug induced birth defect
Drug induced birth defect
Dr. Ashish singh parihar
 
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimenconversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen
pavithra vinayak
 

What's hot (20)

NOMOGRAMS AND TABULATIONS IN DESIGNING DOSAGE REGIMEN.pptx
NOMOGRAMS AND TABULATIONS IN   DESIGNING DOSAGE REGIMEN.pptxNOMOGRAMS AND TABULATIONS IN   DESIGNING DOSAGE REGIMEN.pptx
NOMOGRAMS AND TABULATIONS IN DESIGNING DOSAGE REGIMEN.pptx
 
Individualization of drug dosage regimen
Individualization of drug dosage regimenIndividualization of drug dosage regimen
Individualization of drug dosage regimen
 
Population pharamacokinetics
Population pharamacokineticsPopulation pharamacokinetics
Population pharamacokinetics
 
Therapeutic drug monitoring of seizure disorder drugs
Therapeutic drug monitoring of seizure disorder drugsTherapeutic drug monitoring of seizure disorder drugs
Therapeutic drug monitoring of seizure disorder drugs
 
Individualization of dosage regimen
Individualization of dosage regimenIndividualization of dosage regimen
Individualization of dosage regimen
 
Tdm of cardiovascual drugs
Tdm of cardiovascual drugsTdm of cardiovascual drugs
Tdm of cardiovascual drugs
 
Protocol for tdm
Protocol for tdmProtocol for tdm
Protocol for tdm
 
Adaptive method OR dosing with feedback
Adaptive method OR dosing with feedbackAdaptive method OR dosing with feedback
Adaptive method OR dosing with feedback
 
Dosing in childrens
Dosing in childrensDosing in childrens
Dosing in childrens
 
Dosing in elderly
Dosing in elderly Dosing in elderly
Dosing in elderly
 
Analysis of pk data- Pop PK analysis
Analysis of pk data- Pop PK analysisAnalysis of pk data- Pop PK analysis
Analysis of pk data- Pop PK analysis
 
TDM of drugs used in organ transplantation
TDM of drugs used in organ transplantationTDM of drugs used in organ transplantation
TDM of drugs used in organ transplantation
 
Therapeutic drug monitoring of organ transplantation drugs
Therapeutic drug monitoring of organ transplantation drugsTherapeutic drug monitoring of organ transplantation drugs
Therapeutic drug monitoring of organ transplantation drugs
 
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disordersTherapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
 
Pharmacokinetic and pharmacodynamic correlation
Pharmacokinetic and pharmacodynamic correlationPharmacokinetic and pharmacodynamic correlation
Pharmacokinetic and pharmacodynamic correlation
 
TDM of psychiatric drugs
TDM of psychiatric drugsTDM of psychiatric drugs
TDM of psychiatric drugs
 
Designing of dosage regimen
Designing of dosage regimenDesigning of dosage regimen
Designing of dosage regimen
 
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
Studies of vaccine safety (Pharmacoepidemiology)  V PharmDStudies of vaccine safety (Pharmacoepidemiology)  V PharmD
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
 
Drug induced birth defect
Drug induced birth defectDrug induced birth defect
Drug induced birth defect
 
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimenconversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen
 

Similar to Dosing in childrens

Neonatal pediatric-pharmacology
Neonatal pediatric-pharmacologyNeonatal pediatric-pharmacology
Neonatal pediatric-pharmacology
dunya
 
Pharmacologic considerations in pediatric dentistry
Pharmacologic considerations in pediatric dentistryPharmacologic considerations in pediatric dentistry
Pharmacologic considerations in pediatric dentistry
asjad ansari
 
Paediatric Pharmacology Part-2.pptx
Paediatric Pharmacology Part-2.pptxPaediatric Pharmacology Part-2.pptx
Paediatric Pharmacology Part-2.pptx
65NidheeshKumarPraba
 
Clinical Pharmacokinetics
Clinical PharmacokineticsClinical Pharmacokinetics
Clinical Pharmacokinetics
Nausheen Fatima
 
Paediatric pharmaco-kinetics
Paediatric pharmaco-kinetics Paediatric pharmaco-kinetics
Paediatric pharmaco-kinetics
Ahmad K
 
FDA 2013 Clinical Investigator Training Course: Clinical Discussion of Specia...
FDA 2013 Clinical Investigator Training Course: Clinical Discussion of Specia...FDA 2013 Clinical Investigator Training Course: Clinical Discussion of Specia...
FDA 2013 Clinical Investigator Training Course: Clinical Discussion of Specia...
MedicReS
 
Pediatric pharmacotherapy
Pediatric pharmacotherapyPediatric pharmacotherapy
Pediatric pharmacotherapy
Kaveh Kazemian
 
Pharmacokinetic variability
Pharmacokinetic variabilityPharmacokinetic variability
Pharmacokinetic variability
9993664147
 
Individualization of drug
Individualization of drugIndividualization of drug
Individualization of drug
Dr. Ramesh Bhandari
 
prescribing in paediatrics.pptx
prescribing in paediatrics.pptxprescribing in paediatrics.pptx
prescribing in paediatrics.pptx
AraphaMvugalo
 
General prescribing guidelines for pediatrics, geriatrics and pregnancy
General prescribing guidelines for pediatrics, geriatrics and pregnancyGeneral prescribing guidelines for pediatrics, geriatrics and pregnancy
General prescribing guidelines for pediatrics, geriatrics and pregnancy
Dr. Ankit Gaur
 
Factors modifying drug actions & effects
Factors modifying drug actions & effectsFactors modifying drug actions & effects
Factors modifying drug actions & effects
Eneutron
 
Pediatric Pharmacology:Pharmacokinetics and pharmacodynamics .pptx
Pediatric  Pharmacology:Pharmacokinetics and pharmacodynamics  .pptxPediatric  Pharmacology:Pharmacokinetics and pharmacodynamics  .pptx
Pediatric Pharmacology:Pharmacokinetics and pharmacodynamics .pptx
Azad Haleem
 
Drug use in paediatric &amp; geriatric patients
Drug use in paediatric &amp; geriatric patientsDrug use in paediatric &amp; geriatric patients
Drug use in paediatric &amp; geriatric patients
Viraj Shinde
 
Breastfeeding
BreastfeedingBreastfeeding
Breastfeeding
DaLiitha Pop
 
Analgesic in Pedo-Part 1.pptx
Analgesic in Pedo-Part 1.pptxAnalgesic in Pedo-Part 1.pptx
Analgesic in Pedo-Part 1.pptx
Dr.Vani Bais
 
pediatrics pharmacology
pediatrics pharmacologypediatrics pharmacology
pediatrics pharmacology
Azad Haleem
 
GENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptx
GENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptxGENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptx
GENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptx
kavitharaninachiya
 
Drugs used in special age groups like children, elderly and preganancy
Drugs used in special age groups like children, elderly and preganancyDrugs used in special age groups like children, elderly and preganancy
Drugs used in special age groups like children, elderly and preganancyRoopali Somani
 

Similar to Dosing in childrens (20)

Neonatal pediatric-pharmacology
Neonatal pediatric-pharmacologyNeonatal pediatric-pharmacology
Neonatal pediatric-pharmacology
 
Pharmacologic considerations in pediatric dentistry
Pharmacologic considerations in pediatric dentistryPharmacologic considerations in pediatric dentistry
Pharmacologic considerations in pediatric dentistry
 
Paediatric Pharmacology Part-2.pptx
Paediatric Pharmacology Part-2.pptxPaediatric Pharmacology Part-2.pptx
Paediatric Pharmacology Part-2.pptx
 
Clinical Pharmacokinetics
Clinical PharmacokineticsClinical Pharmacokinetics
Clinical Pharmacokinetics
 
Paediatric pharmaco-kinetics
Paediatric pharmaco-kinetics Paediatric pharmaco-kinetics
Paediatric pharmaco-kinetics
 
FDA 2013 Clinical Investigator Training Course: Clinical Discussion of Specia...
FDA 2013 Clinical Investigator Training Course: Clinical Discussion of Specia...FDA 2013 Clinical Investigator Training Course: Clinical Discussion of Specia...
FDA 2013 Clinical Investigator Training Course: Clinical Discussion of Specia...
 
Pediatric pharmacotherapy
Pediatric pharmacotherapyPediatric pharmacotherapy
Pediatric pharmacotherapy
 
Pharmacokinetic variability
Pharmacokinetic variabilityPharmacokinetic variability
Pharmacokinetic variability
 
Individualization of drug
Individualization of drugIndividualization of drug
Individualization of drug
 
Pediatrics pharmacology
Pediatrics pharmacologyPediatrics pharmacology
Pediatrics pharmacology
 
prescribing in paediatrics.pptx
prescribing in paediatrics.pptxprescribing in paediatrics.pptx
prescribing in paediatrics.pptx
 
General prescribing guidelines for pediatrics, geriatrics and pregnancy
General prescribing guidelines for pediatrics, geriatrics and pregnancyGeneral prescribing guidelines for pediatrics, geriatrics and pregnancy
General prescribing guidelines for pediatrics, geriatrics and pregnancy
 
Factors modifying drug actions & effects
Factors modifying drug actions & effectsFactors modifying drug actions & effects
Factors modifying drug actions & effects
 
Pediatric Pharmacology:Pharmacokinetics and pharmacodynamics .pptx
Pediatric  Pharmacology:Pharmacokinetics and pharmacodynamics  .pptxPediatric  Pharmacology:Pharmacokinetics and pharmacodynamics  .pptx
Pediatric Pharmacology:Pharmacokinetics and pharmacodynamics .pptx
 
Drug use in paediatric &amp; geriatric patients
Drug use in paediatric &amp; geriatric patientsDrug use in paediatric &amp; geriatric patients
Drug use in paediatric &amp; geriatric patients
 
Breastfeeding
BreastfeedingBreastfeeding
Breastfeeding
 
Analgesic in Pedo-Part 1.pptx
Analgesic in Pedo-Part 1.pptxAnalgesic in Pedo-Part 1.pptx
Analgesic in Pedo-Part 1.pptx
 
pediatrics pharmacology
pediatrics pharmacologypediatrics pharmacology
pediatrics pharmacology
 
GENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptx
GENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptxGENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptx
GENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptx
 
Drugs used in special age groups like children, elderly and preganancy
Drugs used in special age groups like children, elderly and preganancyDrugs used in special age groups like children, elderly and preganancy
Drugs used in special age groups like children, elderly and preganancy
 

More from Dr. Ramesh Bhandari

Designing Protocol.pdf
Designing Protocol.pdfDesigning Protocol.pdf
Designing Protocol.pdf
Dr. Ramesh Bhandari
 
Communicable diseases
Communicable diseasesCommunicable diseases
Communicable diseases
Dr. Ramesh Bhandari
 
Causality Assessment ADR.pdf
Causality Assessment ADR.pdfCausality Assessment ADR.pdf
Causality Assessment ADR.pdf
Dr. Ramesh Bhandari
 
Microbiological culture sensitivity tests
Microbiological culture sensitivity testsMicrobiological culture sensitivity tests
Microbiological culture sensitivity tests
Dr. Ramesh Bhandari
 
Respiratory and Intestinal infections
Respiratory and Intestinal infectionsRespiratory and Intestinal infections
Respiratory and Intestinal infections
Dr. Ramesh Bhandari
 
Epidemiology
EpidemiologyEpidemiology
Epidemiology
Dr. Ramesh Bhandari
 
Microbiology
MicrobiologyMicrobiology
Microbiology
Dr. Ramesh Bhandari
 
Nutrition and Food
Nutrition and FoodNutrition and Food
Nutrition and Food
Dr. Ramesh Bhandari
 
Effect of environment on health
Effect of environment on healthEffect of environment on health
Effect of environment on health
Dr. Ramesh Bhandari
 
Vaccine and immunity
Vaccine and immunityVaccine and immunity
Vaccine and immunity
Dr. Ramesh Bhandari
 
Psychosocial pharmacy
Psychosocial pharmacyPsychosocial pharmacy
Psychosocial pharmacy
Dr. Ramesh Bhandari
 
Nutrition
NutritionNutrition
Mother and child health
Mother and child healthMother and child health
Mother and child health
Dr. Ramesh Bhandari
 
Demography, demographic cycle and family planning methods
Demography, demographic cycle and family planning methodsDemography, demographic cycle and family planning methods
Demography, demographic cycle and family planning methods
Dr. Ramesh Bhandari
 
National health policy, MDGs, SDPs, and FIP Development Goals
National health policy, MDGs, SDPs, and FIP Development GoalsNational health policy, MDGs, SDPs, and FIP Development Goals
National health policy, MDGs, SDPs, and FIP Development Goals
Dr. Ramesh Bhandari
 
Concept, Dimension, Determinants, and Indicators of health
Concept, Dimension, Determinants, and Indicators of healthConcept, Dimension, Determinants, and Indicators of health
Concept, Dimension, Determinants, and Indicators of health
Dr. Ramesh Bhandari
 
Social pharmacy, National Health Mission
Social pharmacy, National Health MissionSocial pharmacy, National Health Mission
Social pharmacy, National Health Mission
Dr. Ramesh Bhandari
 
Safety Data Generation
Safety Data GenerationSafety Data Generation
Safety Data Generation
Dr. Ramesh Bhandari
 
ICH Guidelines for Pharmacovigilance
ICH Guidelines for PharmacovigilanceICH Guidelines for Pharmacovigilance
ICH Guidelines for Pharmacovigilance
Dr. Ramesh Bhandari
 
Pharmacovigilance methods
Pharmacovigilance methodsPharmacovigilance methods
Pharmacovigilance methods
Dr. Ramesh Bhandari
 

More from Dr. Ramesh Bhandari (20)

Designing Protocol.pdf
Designing Protocol.pdfDesigning Protocol.pdf
Designing Protocol.pdf
 
Communicable diseases
Communicable diseasesCommunicable diseases
Communicable diseases
 
Causality Assessment ADR.pdf
Causality Assessment ADR.pdfCausality Assessment ADR.pdf
Causality Assessment ADR.pdf
 
Microbiological culture sensitivity tests
Microbiological culture sensitivity testsMicrobiological culture sensitivity tests
Microbiological culture sensitivity tests
 
Respiratory and Intestinal infections
Respiratory and Intestinal infectionsRespiratory and Intestinal infections
Respiratory and Intestinal infections
 
Epidemiology
EpidemiologyEpidemiology
Epidemiology
 
Microbiology
MicrobiologyMicrobiology
Microbiology
 
Nutrition and Food
Nutrition and FoodNutrition and Food
Nutrition and Food
 
Effect of environment on health
Effect of environment on healthEffect of environment on health
Effect of environment on health
 
Vaccine and immunity
Vaccine and immunityVaccine and immunity
Vaccine and immunity
 
Psychosocial pharmacy
Psychosocial pharmacyPsychosocial pharmacy
Psychosocial pharmacy
 
Nutrition
NutritionNutrition
Nutrition
 
Mother and child health
Mother and child healthMother and child health
Mother and child health
 
Demography, demographic cycle and family planning methods
Demography, demographic cycle and family planning methodsDemography, demographic cycle and family planning methods
Demography, demographic cycle and family planning methods
 
National health policy, MDGs, SDPs, and FIP Development Goals
National health policy, MDGs, SDPs, and FIP Development GoalsNational health policy, MDGs, SDPs, and FIP Development Goals
National health policy, MDGs, SDPs, and FIP Development Goals
 
Concept, Dimension, Determinants, and Indicators of health
Concept, Dimension, Determinants, and Indicators of healthConcept, Dimension, Determinants, and Indicators of health
Concept, Dimension, Determinants, and Indicators of health
 
Social pharmacy, National Health Mission
Social pharmacy, National Health MissionSocial pharmacy, National Health Mission
Social pharmacy, National Health Mission
 
Safety Data Generation
Safety Data GenerationSafety Data Generation
Safety Data Generation
 
ICH Guidelines for Pharmacovigilance
ICH Guidelines for PharmacovigilanceICH Guidelines for Pharmacovigilance
ICH Guidelines for Pharmacovigilance
 
Pharmacovigilance methods
Pharmacovigilance methodsPharmacovigilance methods
Pharmacovigilance methods
 

Recently uploaded

Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama UniversityNatural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Akanksha trivedi rama nursing college kanpur.
 
S1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptxS1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptx
tarandeep35
 
Digital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion DesignsDigital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion Designs
chanes7
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
TechSoup
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
 
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat  Leveraging AI for Diversity, Equity, and InclusionExecutive Directors Chat  Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
TechSoup
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
Delapenabediema
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
Sandy Millin
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
SACHIN R KONDAGURI
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
DhatriParmar
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
EduSkills OECD
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
Special education needs
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
Jean Carlos Nunes Paixão
 
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdfMASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
goswamiyash170123
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
vaibhavrinwa19
 
South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)
Academy of Science of South Africa
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
MysoreMuleSoftMeetup
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
Nguyen Thanh Tu Collection
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
Jisc
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
heathfieldcps1
 

Recently uploaded (20)

Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama UniversityNatural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
 
S1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptxS1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptx
 
Digital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion DesignsDigital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion Designs
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
 
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat  Leveraging AI for Diversity, Equity, and InclusionExecutive Directors Chat  Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
 
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdfMASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
 
South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
 

Dosing in childrens

  • 1. DOSING IN CHILDRENS Dr. Ramesh Bhandari Asst. Professor Department of Pharmacy Practice KLE College of Pharmacy, Belagavi
  • 2. Dr. Ramesh Bhandari Asst. Profesor • Infants and children have different dosing requirements than adults. • Paediatric patients were considered mini adults in the past. • Paediatric patient shows physiological variability and so it is important to select an appropriate dose for a paediatric patient.
  • 3. Dr. Ramesh Bhandari Asst. Profesor • The development of organs continue until the age of 12 years. • The variation in body composition and the maturity of liver, kidney, and other organ functions are potential sources of differences in pharmacokinetics with respect to age.
  • 4. Dr. Ramesh Bhandari Asst. Profesor Classification of paediatric patients 1. Preterm Neonate (<37 weeks of gestation) 2. Neonate (Birth to 28 days) 3. Infant & Toddlers (28 days to 23 months) 4. Young child (2 to 5 years) 5. Older child (6 to 11 Years) 6. Adolescent (12 to 18 Years)
  • 5. Dr. Ramesh Bhandari Asst. Profesor • When dosage guidelines are not available for a drug, empirical dose adjustment methods are often used. • These empirical dose adjustment methods are based on body surface area or body weight. • However, pharmacokinetic parameters may vary as a function of age.
  • 6. Dr. Ramesh Bhandari Asst. Profesor • Dosage based on body surface area has the advantage of avoiding some bias due to obesity or unusual body weight, because the height and the weight of the patient are both considered. • The body surface area method gives only a rough estimation of the proper dose, because the pharmacokinetic differences between patients of the same body surface area are not considered.
  • 7. Dr. Ramesh Bhandari Asst. Profesor • Dosage regimens for the newborn, infant, and child must consider the changing physiologic development of the patient and the pharmacokinetics of the specific drug for that age group.
  • 8. Dr. Ramesh Bhandari Asst. Profesor ABSORPTION  Gastric pH is 6-8 at birth, but drops to pH 1–3 within 24 hours of birth  Gastric acid secretion then declines (Achlorhydria) during 8–30 days, and does not approach adult values until approximately 3 years of age  This lower level of gastric acid secretion contributes to the increased bioavailability of acid-labile drugs in neonates compared to older children and adults (E.g.: Penicillin G, Ampicillin)
  • 9. Dr. Ramesh Bhandari Asst. Profesor  Gastric emptying is delayed (upto 6 – 8 hours) and irregular in the neonate and infant, but approaches adult values by 6–8 months of age.  Intestinal motility (peristalsis) is also irregular, unpredictable and only partially dependent on feeding patterns in newborn until 1 year.  In newborns, decreased GI motility can delay drug absorption and result in lower peak plasma drug concentrations, but does not alter the fraction of drug absorbed for most drugs.  In older infants and children, GI transit time may be increased.
  • 10. Dr. Ramesh Bhandari Asst. Profesor Physiologic Variable Age Group PK Result Example ↑ gastric pH Neonates, Infants, Young Children ↑ BA of basic drugs and acid labile drugs ↓ BA of acidic drugs Ampicillin, Penicillin G Phenobarbital (acidic) ↓ gastric and intestinal motility Neonates, Infants Unpredictable BA Digoxin ↑gastric and intestinal motility Older Infants, Children Unpredictable BA Digoxin ↓bile acid production Neonates ↓ BA Vitamin E, Vitamin K Bacterial Flora Neonates and Infants ↑ BA Digoxin
  • 11. Dr. Ramesh Bhandari Asst. Profesor Drug Absorption in Paediatric patients Physiologic Variables Neonate Infants Children Gastric emptying time Gastric pH Intestinal motility Intestinal surface area Muscular blood flow Irregular >5 Reduced Reduced Reduced Increased 2 to 4 Increased Near adult Increased Slightly increased Normal (2-3) Slightly increased Adult pattern Adult pattern
  • 12. Dr. Ramesh Bhandari Asst. Profesor Paediatric Changes in route of administration Parameter Neonate Infants Children Oral absorption IM absorption Percutaneous absorption Rectal absorption Erratic or reduced variable Increased Very efficient ↑ rate Increased Increased Efficient Near adult pattern Adult pattern Near Adult pattern Near adult pattern
  • 13. Dr. Ramesh Bhandari Asst. Profesor Examples Gastrointestinal Drug Absorption Increased in Newborns Infants = adults Decreased in newborns Penicillin Theophylline Phenytoin Ampicillin Sulfonamides Acetaminophen Erythromycin Phenobarbitol Digoxin Zidovudine
  • 14. Dr. Ramesh Bhandari Asst. Profesor DISTRIBUTION • Some of the factors that determine drug distribution within the body are subject to change with age. • These includes vascular perfusion, body composition, tissue binding characteristics and the extent of plasma protein binding.
  • 15. Dr. Ramesh Bhandari Asst. Profesor Extracellular fluid volume and total body water as a percentage of body weight at different life stages Age Total body water (%) Extracellular fluid (%) Preterm Neonates 85 50 Term Neonate 75 45 3 Months 75 30 1 year 60 25 Adult 60 20
  • 16. Dr. Ramesh Bhandari Asst. Profesor Plasma protein binding and drug distribution Parameters Neonate Infants Children Plasma Albumin and total Globulin Decreased Approx. Normal Approx adult Total protein Decreased Decreased Approx adult Adipose Tissue Less Decreased Reduced Total Body water Increased Increased Approx adult Extracellular water Increased Increased Approx adult Hydrophilic drugs Vd Increased Increased Slightly increased Hydrophobic drugs Vd Decreased Decreased Slightly decreased
  • 17. Dr. Ramesh Bhandari Asst. Profesor METABOLISM • At birth, majority of the metabolic enzyme systems are either absent or present in considerably reduced amounts (20 % - 70 %) compared to adults (Exemptions: Sulphate conjugation is more). • This reduced capacity for metabolic degradation at birth is followed by dramatic increase in the metabolic rate in the older infant and young child. • In the age group 1-9 years in particular metabolic clearance of drugs is shown to be greater than in adults as shown by Theophylline, phenytoin and carbamazepine.
  • 18. Dr. Ramesh Bhandari Asst. Profesor Example Theophylline dosage in children older than 1 year Age Dosage (mg/kg/day) 1-9 years 24 9-12 years 20 12-16 years 18 Adult 13
  • 19. Dr. Ramesh Bhandari Asst. Profesor • Glucuronidation is very less. Therefore chloramphenicol is not bound extensively and so poor elimination results in accumulation of chloramphenicol that leads to Gray baby syndrome. • Drugs that are extensively metabolized by liver should be administered cautiously like caffeine, lidocaine, chloramphenicol.
  • 20. Dr. Ramesh Bhandari Asst. Profesor Parameter Neonate Infants Children Liver/body weight ratio Cytochrome P450 activity Hepatic blood flow Phase II enzyme activity Metabolic rates Increased Reduced Reduced Reduced Reduced Increased Increased Increased Increased Increased Slightly increased Slightly increased Approx. Normal Approx. Normal Approx. Normal
  • 21. Dr. Ramesh Bhandari Asst. Profesor EXCRETION • The anatomical and functional immaturity of the kidneys at birth limits the renal excretory capacity. • Younger than 3-6 months, the GFR rate is lower than that of adults. • Generally the complete maturation of glomerular and tubular function is reached after only towards 12-18 months of age.
  • 22. Dr. Ramesh Bhandari Asst. Profesor Renal Clearance of Gentamicin Plasma Half life (in hours) Small premature infants weighing less than 1.5 kg 11.5 Small premature infants weighing 1.5-2 kg 8 Term infants and large premature infants less than1 week of age 5.5 Infants 1 week to months 3-3.5 Infants more than months to adulthood 2-3
  • 23. Dr. Ramesh Bhandari Asst. Profesor Therapeutic Problem in childrens Sampling blood is difficult. Alternative source to be considered like urine or saliva. While selecting dosage form oral dosage forms are more preferred than intravenous.
  • 24. Dr. Ramesh Bhandari Asst. Profesor Factors to be considered while selecting dosage regimen for children i. Age ii. Weight or Body surface area iii. Dosage form or formulation iv. Route of administration v. Pharmacokinetics vi. Interactions
  • 25. Dr. Ramesh Bhandari Asst. Profesor Some useful formulas for Calculating child dose Fried’s rule for infants Age in months X Adult Dose = Dose for Infant 150
  • 26. Dr. Ramesh Bhandari Asst. Profesor Young’s rule Age (in Years) X Adult Dose = Child dose Age (in years) + 12
  • 27. Dr. Ramesh Bhandari Asst. Profesor Child dose based on BSA BSA of child (m2) X Adult Dose = Child dose 1.73 M2 Haycock formula for BSA: BSA = 0.024265 X W0.5378 X H0.3964
  • 29. Dr. Ramesh Bhandari Asst. Profesor Practice Problem The elimination half-life of penicillin G is 0.5 hour in adults and 3.2 hours in neonates (0–7 days old). Assuming that the normal adult dose of penicillin G is 4 mg/kg every 4 hours, calculate the dose of penicillin G for an 11-lb infant.